A Phase 1a/1b Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Advanced Malignant Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Oct 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs IBI 322 (Primary)
Indications Carcinoma; Cervical cancer; Head and neck cancer; Liver cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Innovent Biologics

06 Oct 2023 Status changed from active, no longer recruiting to completed.
15 Sep 2022 Status changed from recruiting to active, no longer recruiting.
13 Apr 2022 Interim results As the data cut-off date from early dose escalation/expansion part of the study on October 12, 2021 presented at the 113th Annual Meeting of the American Association for Cancer Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com